A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancerWolfgang Janni, Christos Papadimitriou, Michelle DeSilvio et al.|Breast Cancer Research and Treatment|2014Cited by 27
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancerWolfgang Janni, Christos Papadimitriou, Tomasz Sarosiek et al.|The Breast|2015Cited by 11
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).Christos Papadimitriou, Wolfgang Janni, Tomasz Sarosiek et al.|Journal of Clinical Oncology|2013Cited by 6
Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)W Janni, C Papadimitriou, Tomasz Sarosiek et al.|Cancer Research|2012Cited by 2
OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer.W Janni, FJ Sapunar, Joanna Pikiel et al.|Cancer Research|2011Cited by 1